Assessing methylphenidate preference in ADHD patients using a choice procedure

Psychopharmacology

Volumn 175, Issue 4, 2004, Pages 391-398

  Fredericks, Emily MacDonald ^a   Kollins, Scott H ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abuse potential; ADHD; Drug preference; Methylphenidate; Reinforcing effects

Indexed keywords

ALPRAZOLAM; COCAINE; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; DRUG ABUSE; DRUG EFFICACY; DRUG PREFERENCE; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; REINFORCEMENT; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; QUESTIONNAIRES; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE-RELATED DISORDERS;

EID: 5444256128     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1838-2     Document Type: Article

References (67)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Author: Washington, DC
2. Babcock Q, Bryne T (2000) Student perceptions of methylphenidate abuse at a Public Liberal Arts College. J Am Coll Health 49:143-146
3. Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13-S40
4. Barkley RA (1990) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford, New York
5. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman B, Doyle A (1993) Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150:1792-1798
6. Chait LD (1994) Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 5:281-288
7. Chait LD, Uhlenhuth EH, Johanson CE (1987) Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 242:777-783
8. Conners CK, Erhardt D, Epstein JN, Parker JD, Sitarenios G, Sparrow E (1999a) Self-ratings of ADHD symptoms in adults. I. Factor structure and normative data. J Atten Disord 3:141-151
9. Conners CK, Erhardt D, Sparrow E (1999b) Conners's adult ADHD rating scales (CAARS). Multi-health systems. North Tonawanda, NY
10. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder [comment]. Lancet 354:2132-2133
11. Drug Enforcement Administration (2000): DEA congressional testimony by Terrance Woodworth before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families. World Wide Web url: http://www. usdoj.gov/dea/pubs/cngrtest/ct051600.htm. May 16, 2000
12. DuPaul GJ, Barkley RA, Connor DF (1998) Stimulants. In: Barkley RA (ed) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd edn. Guilford, New York, pp 510-551
13. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004). Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24-29
14. Fischman MW (1989) Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. In: Fischman MW, Mello NK (eds) Testing for the abuse liability of drugs in humans. DHHS Publication No. (ADM) 89-1613. Nida Research Monograph 92, pp 211-230
15. Fischman MW, Mello NK (1989) Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Monograph No. 92, Department of Health and Human Services Publication No. (ADM) 1989; 89-1613. US Government Printing Office, Washington, DC
16. Foltin RW, Fischman MW (1991) Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans. Br J Addict 86:1633-1640
17. Fulton AI, Yates WR (1988) Family abuse of methylphenidate. Am Fam Physician 38:143-145
18. Gittelman R, Mannuzza S, Shenkar R, Bonagura N (1985) Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry 42:937-947
19. Gomez TH, Roache JD, Meisch RA (2002) Orally delivered alprazolam, diazepam, and triazolam as reinforcers in rhesus monkeys. Psychopharmacology 161:86-94
20. Greenhill LL (1998) Childhood attention deficit hyperactivity disorder: pharmacological treatments. In: Nathan PE, Gorman JM (eds) A guide to treatments that work. Oxford University, New York, pp 42-64
21. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
22. Heishman SJ, Henningfield JE (1991) Discriminative stimulus effects of d-amphetamine, methylphenidate and diazepam in humans. Psychopharmacology 103:436-442
23. Jaffe SL (1991) Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 30:773-775
24. Johanson CE, Uhlenhuth EH (1982) Drug preference in humans. Fed Proc 41:228-233
25. Johanson CE, deWit H (1989) The use of choice procedures for assessing the reinforcing properties of drugs in humans. In: Fischman MW, Mello NK (eds) Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Research Monograph No. 92. US Government Printing Office, Washington, DC, pp 171-210
26. Johanson CE, Kilgore K, Uhlenhuth EH (1983) Assessment of dependence potential of drugs in humans using multiple indices. Psychopharmacology 81:144-149
27. Juergens S (1991) Alprazolam and diazepam: addiction potential. J Subst Abuse Treat 8:43-51
28. Kollins SH (2003) Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 64[Suppl 11]:14-18
29. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367-374
30. Kollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Beh 68:611-627
31. Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31:533-544
32. Llana ME, Crismon ML (1999) Methylphenidate: increased abuse or appropriate use? J Am Pharmacol Assoc 39:526-530
33. Marsh LD, Key JD, Payne TP (2000) Methylphenidate misuse in substance abusing adolescents. J Child Adolesc Subst Abus 9:1-14
34. Martin WR, Sloan JW, Sapira JD, Jasiniski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12:245-258
35. McCann BS, Scheele L, Ward N, Roy-Byrne P (2000) Discriminant validity of the Wender Utah rating scale for attention-deficit/ hyperactivity disorder in adults. J Neuropsychiatry Clin Neurosci 12:240-245
36. McCracken SG, deWit H, Uhlenhuth EH, Johanson CE (1990) Preference for diazepam in anxious adults. J Clin Psychopharmacol 10: 190-196
37. McNair DM, Lorr M, Droppleman LF (1971) Profile of mood states (manual). Educational and Industrial Testing Services, San Diego
38. Musser CJ, Ahmann FW, Mundt P, Broste SK, Mueller-Rizner N (1998) Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 19:187-192
39. Parran TV Jr, Jasinski DR (1991) Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 151:781-783
40. Popper CW (1995) Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 5:157-166
41. Rappley MD (1997) Safety issues in the use of methylphenidate. Drug Saf 17:143-148
42. Rapport MD, DuPaul GJ, Stoner G, Birmingham BK, Masse G (1985) Attention deficit disorder with hyperactivity: differential effects of methylphenidate on impulsivity. Pediatrics 76:938-943
43. Roache JD, Stanley MA, Creson DR, Shah NN, Meisch RA (1997) Alprazolam-reinforced medication use in outpatients with anxiety. Drug Alcohol Depend 45:143-155
44. Robinson LM, Sclar DA, Skaer TL, Galin RS (1999) National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr 38:209-217
45. Roehrs T, Papineau K, Rosenthal L, Roth T (1999) Sleepiness and the reinforcing and subjective effects of methylphenidate. Exp Clin Psychopharmacol 7:145-150
46. Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, buproprion, and triazolam in d-amphetamine trained humans. Exp Clin Psychopharmacol 6:32-44
47. Rush CR, Essman WD, Simpson CA, Baker RW (2001) Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug abusing humans. J Clin Psychopharmacol 21:273-286
48. Safer DJ (2000) Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12:55-62
49. Safer DJ, Zito JM, Fine EM (1996) Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98:1084-1088
50. Silverman K, Kirby K, Griffiths RR (1994a) Modulation of drug reinforcement by behavioral requirements following drug ingestion. Psychopharmacology 114:243-247
51. Silverman K, Mumford GK, Griffiths RR (1994b) Enhancing caffeine reinforcement by behavioral requirements following drug ingestion. Psychopharmacology 114:424-432
52. Spencer TW et al (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434-443
53. Spiga R, Roache JD (1997) Human drug self-administration: a review and methodological critique. In: Johnson BA, Roache JD (eds) Drug addiction and its treatment: nexus of neuroscience. Lippincott-Raven Publishers, Philadelphia, pp 39-71
54. Stein MA, Sandoval R, Szumowski E, Roizen N, Reinecke MA, Blondis TA, Klein Z (1995) Psychometric characteristics of the Wender Utah rating scale (WURS): reliability and factor structure for men and women. Psychopharmacol Bull 31:425-433
55. Stoops WW, Glaser PEA, Rush CR (2003) Reinforcing, subjectrated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend 71:179-186
56. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey SL, Hitzemann R, Gifford AN, Pappas NR (1999) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high." J Pharm Exp Ther 288:14-20
57. Volkow ND, Wang GJ, Fowler JS, Thanos P, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas N (2002) Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46:79-82
58. Ward MF, Wender PH, Reimherr FW (1993) The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150:885-890
59. Wilens TE, Biederman J, Spencer TJ, Prince J (1995) Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 15:270-279
60. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179-185
61. deWit H, Griffiths RR (1991) Testing the abuse liability of anxiolytics and hypnotic drugs in humans. Drug Alcohol Depend 28:83-111
62. deWit H, Johanson CE (1987) A drug preference procedure for use with human volunteers. In: Bozarth M (ed) Methods of assessing the reinforcing properties of abused drugs. Springer-Verlag, New York, pp 559-572
63. deWit H, Uhlenhuth EH, Johanson CE (1984) Lack of preference for flurazepam in normal volunteers. Pharmacol Biochem Behav 21:865-869
64. deWit H, Uhlenhuth EH, Hedeker D, McCracken SG, Johanson CE (1986) Lack of preference for diazepam in anxious volunteers. Arch Gen Psychiatry 43:533-541
65. Woods JH, Winger G (1995) Current benzodiazepine issues. Psychopharmacology 188:107-115
66. Zarin DA, Suarez AP, Pincus HA, Kupersanin BA, Zito JM (1998) Clinical and treatment characteristics of children with attention deficit hyperactivity disorder (ADHD) in psychiatric practice. J Am Acad Child Adolesc Psychiatry 37:1262-1270
67. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030